ODYSSEY clinical trial design: a randomised global study to evaluate the efficacy and safety of dolutegravir-based antiretroviral therapy in HIV-positive children, with nested pharmacokinetic sub-studies to evaluate pragmatic WHO-weight-band based dolutegravir dosing
Cecilia L Moore, Anna Turkova, Hilda Mujuru, Adeodata Kekitiinwa, Abbas Lugemwa, Cissy M Kityo, Linda N Barlow-Mosha, Tim R Cressey, Avy Violari, Ebrahim Variava, Mark F Cotton, Moherndran Archary, Alexandra Compagnucci, Thanyawee Puthanakit, Osee Behuhuma, Yacine Saϊdi, James Hakim, Pauline Amuge, Lorna Atwine, Victor Musiime, David M Burger, Clare Shakeshaft, Carlo Giaquinto, Pablo Rojo, Diana M Gibb, Deborah Ford, ODYSSEY Trial Team
Abstract
Background: Dolutegravir (DTG)-based antiretroviral therapy (ART) is highly effective and well-tolerated in adults and is rapidly being adopted globally. We describe the design of the ODYSSEY trial which evaluates the efficacy and safety of DTG-based ART compared with standard-of-care in children and adolescents. The ODYSSEY trial includes nested pharmacokinetic (PK) sub-studies which evaluated pragmatic World Health Organization (WHO) weight-band-based DTG dosing and opened recruitment to children < 14 kg while dosing was in development.
Methods: ODYSSEY (Once-daily DTG based ART in Young people vS. Standard thErapY) is an open-label, randomised, non-inferiority, basket trial comparing the efficacy and safety of DTG + 2 nucleos(t) ides (NRTIs) versus standard-of-care (SOC) in HIV-infected children < 18 years starting first-line ART (ODYSSEY A) or switching to second-line ART (ODYSSEY B). The primary endpoint is clinical or virological failure by 96 weeks.
Results: Between September 2016 and June 2018, 707 children weighing ≥14 kg were enrolled; including 311 ART-naïve children and 396 children starting second-line. 47% of children were enrolled in Uganda, 21% Zimbabwe, 20% South Africa, 9% Thailand, 4% Europe. 362 (51%) participants were male; median age [range] at enrolment was 12.2 years [2.9-18.0]. 82 (12%) children weighed 14 to < 20 kg, 135 (19%) 20 to < 25 kg, 206 (29%) 25 to < 35 kg, 284 (40%) ≥35 kg. 128 (18%) had WHO stage 3 and 60 (8%) WHO stage 4 disease. Challenges encountered include: (i) running the trial across high- to low-income countries with differing frequencies of standard-of-care viral load monitoring; (ii) evaluating pragmatic DTG dosing in PK sub-studies alongside FDA- and EMA-approved dosing and subsequently transitioning participants to new recommended doses; (iii) delays in dosing information for children weighing 3 to < 14 kg and rapid recruitment of ART-naïve older/heavier children, which led to capping recruitment of participants weighing ≥35 kg in ODYSSEY A and extending recruitment (above 700) to allow for ≥60 additional children weighing between 3 to < 14 kg with associated PK; (iv) a safety alert associated with DTG use during pregnancy, which required a review of the safety plan for adolescent girls.
Conclusions: By employing a basket design, to include ART-naïve and -experienced children, and nested PK sub-studies, the ODYSSEY trial efficiently evaluates multiple scientific questions regarding dosing and effectiveness of DTG-based ART in children.
Trial registration: NCT, NCT02259127 , registered 7th October 2014; EUDRACT, 2014-002632-14, registered 18th June 2014 ( https://www.clinicaltrialsregister.eu/ctr-search/trial/2014-002632-14/ES ); ISRCTN, ISRCTN91737921 , registered 4th October 2014.
Keywords: Basket trial; Dolutegravir; Efficacy; HIV; Paediatric; Pharmacokinetic; Randomized control trial; Safety.
Conflict of interest statement
MFC is a member of an advisory board for ViiV Healthcare and reports grants from ViiV Healthcare and Gilead, outside the submitted work. DMB is a member of an advisory board for Merck and ViiV Healthcare and reports grants from Merck, BMS, Janssen/Tibotec, Gilead and ViiV Healthcare outside the submitted work. All other authors declare that they have no competing interests.
Figures
References
- World Health Organization (WHO) Guideline on when to start antiretroviral therapy and on pre-exposure prophylaxis for HIV. Geneva: WHO; 2016.
- UNAIDS . Aids by the Numbers. 2016.
- UNAIDS . Children and HIV. 2016.
- Clinton Health Access Initiative (CHAI) ARV Market Report: The state of the antiretroviral drug market in low- and middle-income countries, 2016–2021. 2017.
- Boerma RS, Boender TS, Bussink AP, Calis JC, Bertagnolio S, Rinke de Wit TF, et al. Suboptimal viral suppression rates among HIV-infected children in low- and middle-income countries: a meta-analysis. Clin Infect Dis. 2016;63(12):1645–1654. doi: 10.1093/cid/ciw645.
- Boerma RS, Sigaloff KC, Akanmu AS, Inzaule S, Boele van Hensbroek M, Rinke de Wit TF, et al. Alarming increase in pretreatment HIV drug resistance in children living in sub-Saharan Africa: a systematic review and meta-analysis. J Antimicrob Chemother. 2017;72(2):365–371. doi: 10.1093/jac/dkw463.
- Jordan MR, Penazzato M, Bertagnolio S, Cournil A, Peeters M, Vubil A, et al. Human immunodeficiency virus (HIV) drug resistance in African infants and young children newly diagnosed with HIV: a multicountry analysis. Clin Infect Dis. 2017;65(12):2018–2025. doi: 10.1093/cid/cix698.
- Stellbrink HJ, Reynes J, Lazzarin A, Voronin E, Pulido F, Felizarta F, et al. Dolutegravir in antiretroviral-naive adults with HIV-1: 96-week results from a randomized dose-ranging study. AIDS. 2013;27(11):1771–1778. doi: 10.1097/QAD.0b013e3283612419.
- Raffi F, Jaeger H, Quiros-Roldan E, Albrecht H, Belonosova E, Gatell JM, et al. Once-daily dolutegravir versus twice-daily raltegravir in antiretroviral-naive adults with HIV-1 infection (SPRING-2 study): 96 week results from a randomised, double-blind, non-inferiority trial. Lancet Infect Dis. 2013;13(11):927–935. doi: 10.1016/S1473-3099(13)70257-3.
- Raffi F, Rachlis A, Stellbrink HJ, Hardy WD, Torti C, Orkin C, et al. Once-daily dolutegravir versus raltegravir in antiretroviral-naive adults with HIV-1 infection: 48 week results from the randomised, double-blind, non-inferiority SPRING-2 study. Lancet. 2013;381(9868):735–743. doi: 10.1016/S0140-6736(12)61853-4.
- Eron JJ, Clotet B, Durant J, Katlama C, Kumar P, Lazzarin A, et al. Safety and efficacy of dolutegravir in treatment-experienced subjects with raltegravir-resistant HIV type 1 infection: 24-week results of the VIKING study. J Infect Dis. 2013;207(5):740–748. doi: 10.1093/infdis/jis750.
- Walmsley SL, Antela A, Clumeck N, Duiculescu D, Eberhard A, Gutierrez F, et al. Dolutegravir plus abacavir-lamivudine for the treatment of HIV-1 infection. N Engl J Med. 2013;369(19):1807–1818. doi: 10.1056/NEJMoa1215541.
- Wiznia AA, Alvero C, Fenton T, George K, Townley E, Hazra R, et al. IMPAACT 1093: Dolutegravir in 6-12 year old HIV infected children: 48-week results conference on retroviruses and opportunistic infections. Boston: 23rd Conference on Retroviruses and Opportunistic Infections (CROI 2016); 2016.
- Rutherford GW, Horvath H. Dolutegravir plus two nucleoside reverse transcriptase inhibitors versus Efavirenz plus two nucleoside reverse transcriptase inhibitors as initial antiretroviral therapy for people with HIV: a systematic review. PLoS One. 2016;11(10):e0162775. doi: 10.1371/journal.pone.0162775.
- Zash R. Surveillance for neural tube defects following antiretroviral exposure from conception, the Tsepamo study (Botswana) 22nd international AIDS conference; 23–27 July 2018. Amsterdam: 22nd International AIDS Conference (IAS 2018);2018.
- Zash R, Makhema J, Shapiro RL. Neural-tube defects with Dolutegravir treatment from the time of conception. N Engl J Med. 2018;379(10):979–981. doi: 10.1056/NEJMc1807653.
- Zash R, Holmes L, Diseko M, Jacobson DL, Brummel S, Mayondi G, et al. Neural-tube defects and antiretroviral treatment regimens in Botswana. N Engl J Med. 2019;381(9):827–840. doi: 10.1056/NEJMoa1905230.
- WHO Statement on DTG . Geneva 18 May 2018- Potential safety issue affecting women living with HIV using dolutegravir at the time of conception [press release] Geneva: WHO; 2018.
- World Health Organization . Policy brief: update on antiretroviral regimens for treating and preventing HIV infection and update on early infant diagnosis of HIV: interim guidance. Geneva: World Health Organization: Licence: CC BY-NC-SA 3.0 IGO; 2018.
- Zash R, Holmes L, Diseko M, Jacobson DL, Mayondi G, Isaacson A, et al. Update on neural tube defects with antiretroviral exposure in the Tsepamo study, Botswana. 2020.
- Clinton Health Access Initiative (CHAI) HIV Market Report: The state of the HIV treatment, testing, and prevention markets in low-and middle-income countries. 2020.
- Ford D, Turner R, Turkova A, Penazzato M, Musiime V, Bwakura-Dangarembizi M, et al. Optimizing Clinical Trial Design to Maximize Evidence Generation in Pediatric HIV. J Acquir Immune Defic Syndr (1999) 2018;78(Suppl 1):S40–Ss8. doi: 10.1097/QAI.0000000000001748.
- Turkova A, Bollen P, Kaudha E, Chidziva E, Lugemwa A, Kekitiinwa A, et al. Steady-state pharmacokinetics and early safety data in HIV-infected African children weighing ≥25kg after switching to 50mg film-coated dolutegravir tablets in the ODYSSEY trial. 10th International Workshop on HIV Pediatrics; July 20–21 2018. Amsterdam: Reviews in Antiviral Therapy & Infectious Diseases; 2018. p. 5.
- Network IMPAACT. P1093 (DAIDS ID 11773): Phase I/II, Multi-Center, Open-Label, Pharmacokinetic Safety, Tolerability and Antiviral Activity of Dolutegravir, a Novel Integrase Inhibitor, in Combination Regimens in HIV-1 Infected Infants, Children and Adolescents. IMPAACT; [Available from: . Accessed 27 Feb 2019.
- Parienti J-J, Verdon R, Massari V. Methodological standards in non-inferiority AIDS trials: moving from adherence to compliance. BMC Med Res Methodol. 2006;6(1):46. doi: 10.1186/1471-2288-6-46.
- Food Drug Administration Center for Drugs Evaluation Research . Human immunodeficiency Virus-1 infection: developing antiretroviral drugs for treatment - guidance for industry. Maryland: FDA; 2015.
- Kekitiinwa A, Cook A, Nathoo K, Mugyenyi P, Nahirya-Ntege P, Bakeera-Kitaka S, et al. Routine versus clinically driven laboratory monitoring and first-line antiretroviral therapy strategies in African children with HIV (ARROW): a 5-year open-label randomised factorial trial. Lancet. 2013;381(9875):1391–1403. doi: 10.1016/S0140-6736(12)62198-9.
- Bollen P, Turkova A, Mujuru H, Musiime V, Amuge P, Lugemwa A, et al. Steady-state pharmacokinetics and early safety data in HIV-infected African children weighing 14 to <25kg on film-coated dolutegravir 25mg tablets in the ODYSSEY trial 10th International Workshop on HIV Pediatrics; July 20–21 2018. Amterdam: Reviews in Antiviral Therapy & Infectious Diseases; 2018. p. 27.
- Bollen P, Turkova A, Mujuru H, Kaudha E, Lugemwa A, Amuge P, et al. Adult Dolutegravir 50mg Tablets in Children Living with HIV Weighing 20 to <25kg. Seattle: Conference on Retroviruses and Opportunistic Infections (CROI); 4–7 March 2019; 2019.
- Waalewijn H, Bollen PDJ, Moore C, Kekitiinwa A, Amuge P, Mujuru H, et al. Pharmacokinetics of dolutegravir 5mg dispersible tablets in children weighing 6 to < 20kg dosed using WHO weight bands. Mexico City: 10th IAS Conference on HIV Science; 21–24 July2019; 2019.
- Waalewijn H, Mujuru H, Amuge P, Cotton M, Bollen P, Chan M, et al. Adequate dolutegravir exposure dosed BID with rifampicin in children 6 to <18 years. Boston: Conference on Retroviruses and Opportunistic Infections; March 8–11, 2020; 2020.
- Lanyon C, Seeley J, Namukwaya S, Musiime V, Paparini S, Nakyambadde H, et al. “Because we all have to grow up”: supporting adolescents in Uganda to develop core competencies to transition towards managing their HIV more independently. J Int AIDS Soc. 2020;23(Suppl 5):e25552.
- World Health Organization (WHO). Consolidated guidelines on the use of antiretroviral drugs for treating and preventing HIV infection: recommendations for a public health approach. 2nd ed. Geneva; 2016.
- Turner R, White I, ODYSSEY trial team . IMPART trial team. Analysing small groups within clinical trials, while borrowing information from larger groups. Leuven: 40th Annual Conference of the International Society for Clinical Biostatistics; 14–18 July 2019; 2019.
- de Onis M, Onyango A, Borghi E, Siyam A, Nishida C, Siekmann J. Development of a WHO growth reference for school-aged children and adolescents. Bull World Health Organ. 2007;85:661–668.
- Penazzato M. Opportunities for the use of new ARVs for infants, children and adolescents and updated guidance on early infant diagnosis (NAT) Amsterdam: 22nd International AIDS Conference; 23 July 2018; 2018.
Source: PubMed